Do analysts prefer ICCC or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer ICCC or TXMD?

In the previous week, ImmuCell had 5 more articles in the media than TherapeuticsMD. MarketBeat recorded 7 mentions for ImmuCell and 2 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.91 beat ImmuCell's score of 0.64 indicating that TherapeuticsMD is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuCell 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TherapeuticsMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TXMD or NMRA?

Neumora Therapeutics has a consensus price target of $6.57, suggesting a potential upside of 1,393.51%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Neumora Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Does the media refer more to TXMD or NMRA?

In the previous week, Neumora Therapeutics had 3 more articles in the media than TherapeuticsMD. MarketBeat recorded 5 mentions for Neumora Therapeutics and 2 mentions for TherapeuticsMD. Neumora Therapeutics' average media sentiment score of 1.30 beat TherapeuticsMD's score of 0.91 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TherapeuticsMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neumora Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TXMD or CGTX?

Cognition Therapeutics has a consensus price target of $3.33, suggesting a potential upside of 329.17%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media favor TXMD or CGTX?

In the previous week, Cognition Therapeutics had 5 more articles in the media than TherapeuticsMD. MarketBeat recorded 7 mentions for Cognition Therapeutics and 2 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.91 beat Cognition Therapeutics' score of 0.76 indicating that TherapeuticsMD is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TherapeuticsMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cognition Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TXMD or ZYBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, TXMD or ZYBT?

TherapeuticsMD has higher earnings, but lower revenue than Zhengye Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TherapeuticsMD $3.27M 6.90 -$570K $0.02 97.50 Zhengye Biotechnology $16.64M 4.63 -$9.98M N/A N/A

Does the media refer more to TXMD or ZYBT?

In the previous week, Zhengye Biotechnology had 3 more articles in the media than TherapeuticsMD. MarketBeat recorded 5 mentions for Zhengye Biotechnology and 2 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.91 beat Zhengye Biotechnology's score of 0.41 indicating that TherapeuticsMD is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TherapeuticsMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer RFL or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, RFL or TXMD?

TherapeuticsMD has higher revenue and earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rafael $920K 80.20 -$30.52M -$0.68 N/A TherapeuticsMD $3.27M 6.97 -$570K $0.02 98.50

Is RFL or TXMD more profitable?

TherapeuticsMD has a net margin of -6.64% compared to Rafael's net margin of -3,321.74%. TherapeuticsMD's return on equity of -1.09% beat Rafael's return on equity. Company Net Margins Return on Equity Return on Assets Rafael -3,321.74% -41.27% -35.32% TherapeuticsMD -6.64% -1.09% -0.78%

Does the media refer more to RFL or TXMD?

In the previous week, Rafael had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 3 mentions for Rafael and 2 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.91 beat Rafael's score of 0.00 indicating that TherapeuticsMD is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rafael 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TherapeuticsMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

TherapeuticsMD (TXMD) Competitors

$1.93 -0.04 (-2.03%)

As of 04:00 PM Eastern

Compare

TXMD vs. ICCC, NMRA, CGTX, ZYBT, and RFL

Should you buy TherapeuticsMD stock or one of its competitors? TherapeuticsMD's main competitors and comparable companies include ImmuCell (ICCC), Neumora Therapeutics (NMRA), Cognition Therapeutics (CGTX), Zhengye Biotechnology (ZYBT), and Rafael (RFL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does TherapeuticsMD compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

TherapeuticsMD has lower revenue, but higher earnings than ImmuCell. TherapeuticsMD is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.53	-$1.04M	$0.08	134.38
TherapeuticsMD	$3.27M	6.97	-$570K	$0.02	98.50

ImmuCell has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

13.5% of ImmuCell shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 5.7% of ImmuCell shares are held by insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, ImmuCell had 5 more articles in the media than TherapeuticsMD. MarketBeat recorded 7 mentions for ImmuCell and 2 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.91 beat ImmuCell's score of 0.64 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmuCell	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TherapeuticsMD	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmuCell has a net margin of 2.57% compared to TherapeuticsMD's net margin of -6.64%. ImmuCell's return on equity of 2.69% beat TherapeuticsMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.69%	1.76%
TherapeuticsMD	-6.64%	-1.09%	-0.78%

Summary

ImmuCell beats TherapeuticsMD on 9 of the 14 factors compared between the two stocks.

How does TherapeuticsMD compare to Neumora Therapeutics?

TherapeuticsMD (NASDAQ:TXMD) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

In the previous week, Neumora Therapeutics had 3 more articles in the media than TherapeuticsMD. MarketBeat recorded 5 mentions for Neumora Therapeutics and 2 mentions for TherapeuticsMD. Neumora Therapeutics' average media sentiment score of 1.30 beat TherapeuticsMD's score of 0.91 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TherapeuticsMD	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neumora Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TherapeuticsMD has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.95, indicating that its share price is 195% more volatile than the broader market.

Neumora Therapeutics has a consensus price target of $6.57, suggesting a potential upside of 1,393.51%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Neumora Therapeutics has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. TherapeuticsMD's return on equity of -1.09% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
Neumora Therapeutics	N/A	-242.28%	-131.32%

TherapeuticsMD has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.27M	6.90	-$570K	$0.02	97.50
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Neumora Therapeutics beats TherapeuticsMD on 10 of the 16 factors compared between the two stocks.

How does TherapeuticsMD compare to Cognition Therapeutics?

TherapeuticsMD (NASDAQ:TXMD) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Cognition Therapeutics has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. TherapeuticsMD's return on equity of -1.09% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
Cognition Therapeutics	N/A	-50.17%	-40.22%

TherapeuticsMD has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.27M	6.97	-$570K	$0.02	98.50
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A

TherapeuticsMD has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market.

Cognition Therapeutics has a consensus price target of $3.33, suggesting a potential upside of 329.17%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Comparatively, 11.1% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Cognition Therapeutics had 5 more articles in the media than TherapeuticsMD. MarketBeat recorded 7 mentions for Cognition Therapeutics and 2 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.91 beat Cognition Therapeutics' score of 0.76 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TherapeuticsMD	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cognition Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cognition Therapeutics beats TherapeuticsMD on 8 of the 14 factors compared between the two stocks.

How does TherapeuticsMD compare to Zhengye Biotechnology?

TherapeuticsMD (NASDAQ:TXMD) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

30.7% of TherapeuticsMD shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.31, suggesting that its share price is 331% less volatile than the broader market.

TherapeuticsMD has higher earnings, but lower revenue than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.27M	6.90	-$570K	$0.02	97.50
Zhengye Biotechnology	$16.64M	4.63	-$9.98M	N/A	N/A

Zhengye Biotechnology has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. Zhengye Biotechnology's return on equity of 0.00% beat TherapeuticsMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
Zhengye Biotechnology	N/A	N/A	N/A

In the previous week, Zhengye Biotechnology had 3 more articles in the media than TherapeuticsMD. MarketBeat recorded 5 mentions for Zhengye Biotechnology and 2 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.91 beat Zhengye Biotechnology's score of 0.41 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TherapeuticsMD	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zhengye Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

TherapeuticsMD beats Zhengye Biotechnology on 6 of the 11 factors compared between the two stocks.

How does TherapeuticsMD compare to Rafael?

Rafael (NYSE:RFL) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Rafael had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 3 mentions for Rafael and 2 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.91 beat Rafael's score of 0.00 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rafael	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TherapeuticsMD	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rafael has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

11.3% of Rafael shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 32.9% of Rafael shares are owned by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

TherapeuticsMD has higher revenue and earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$920K	80.20	-$30.52M	-$0.68	N/A
TherapeuticsMD	$3.27M	6.97	-$570K	$0.02	98.50

TherapeuticsMD has a net margin of -6.64% compared to Rafael's net margin of -3,321.74%. TherapeuticsMD's return on equity of -1.09% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
TherapeuticsMD	-6.64%	-1.09%	-0.78%

Summary

TherapeuticsMD beats Rafael on 10 of the 13 factors compared between the two stocks.

Get TherapeuticsMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TXMD vs. The Competition

Export

Metric	TherapeuticsMD	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$22.34M	$12.65B	$7.43B	$12.93B
Dividend Yield	N/A	2.63%	2.52%	19.59%
P/E Ratio	96.50	805.28	274.96	25.39
Price / Sales	6.83	837.08	608.73	90.53
Price / Cash	42.01	84.08	76.68	52.75
Price / Book	0.83	9.32	10.32	6.02
Net Income	-$570K	$2.83B	$3.49B	$380.68M
7 Day Performance	-3.98%	-3.43%	-2.54%	-3.01%
1 Month Performance	-10.65%	-7.27%	-6.87%	-5.59%
1 Year Performance	86.47%	-5.47%	1.81%	-5.23%

TherapeuticsMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TXMD TherapeuticsMD	1.3352 of 5 stars	$1.93 -2.0%	N/A	+89.4%	$22.34M	$3.27M	96.50	420
ICCC ImmuCell	0.7416 of 5 stars	$10.79 +12.4%	N/A	+64.9%	$87.19M	$27.64M	120.00	73	Gap Up High Trading Volume
NMRA Neumora Therapeutics	4.2332 of 5 stars	$0.37 -15.3%	$6.57 +1,675.1%	-80.3%	$82.17M	N/A	N/A	63	News Coverage Positive News Gap Up
CGTX Cognition Therapeutics	2.206 of 5 stars	$0.80 -6.4%	$3.33 +315.8%	-55.4%	$81.49M	N/A	N/A	14	Gap Down High Trading Volume
ZYBT Zhengye Biotechnology	0.4833 of 5 stars	$1.48 -12.4%	N/A	-47.1%	$80.09M	$16.64M	N/A	269

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TXMD) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TherapeuticsMD (TXMD) Competitors

TXMD vs. ICCC, NMRA, CGTX, ZYBT, and RFL

How does TherapeuticsMD compare to ImmuCell?

Summary

How does TherapeuticsMD compare to Neumora Therapeutics?

Summary

How does TherapeuticsMD compare to Cognition Therapeutics?

Summary

How does TherapeuticsMD compare to Zhengye Biotechnology?

Summary

How does TherapeuticsMD compare to Rafael?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TherapeuticsMD (TXMD) Competitors

TXMD vs. ICCC, NMRA, CGTX, ZYBT, and RFL

How does TherapeuticsMD compare to ImmuCell?

Which has better earnings & valuation, ICCC or TXMD?

Which has more risk & volatility, ICCC or TXMD?

Do institutionals and insiders hold more shares of ICCC or TXMD?

Do analysts prefer ICCC or TXMD?

Does the media prefer ICCC or TXMD?

Is ICCC or TXMD more profitable?

Summary

How does TherapeuticsMD compare to Neumora Therapeutics?

Does the media refer more to TXMD or NMRA?

Which has more risk & volatility, TXMD or NMRA?

Do analysts prefer TXMD or NMRA?

Is TXMD or NMRA more profitable?

Which has better valuation & earnings, TXMD or NMRA?

Do insiders & institutionals hold more shares of TXMD or NMRA?

Summary

How does TherapeuticsMD compare to Cognition Therapeutics?

Is TXMD or CGTX more profitable?

Which has preferable earnings and valuation, TXMD or CGTX?

Which has more risk & volatility, TXMD or CGTX?

Do analysts recommend TXMD or CGTX?

Do institutionals & insiders have more ownership in TXMD or CGTX?

Does the media favor TXMD or CGTX?

Summary

How does TherapeuticsMD compare to Zhengye Biotechnology?

Do institutionals and insiders have more ownership in TXMD or ZYBT?

Do analysts recommend TXMD or ZYBT?

Which has more risk and volatility, TXMD or ZYBT?

Which has preferable earnings & valuation, TXMD or ZYBT?

Is TXMD or ZYBT more profitable?

Does the media refer more to TXMD or ZYBT?

Summary

How does TherapeuticsMD compare to Rafael?

Do analysts prefer RFL or TXMD?

Does the media refer more to RFL or TXMD?

Which has more volatility & risk, RFL or TXMD?

Do insiders and institutionals hold more shares of RFL or TXMD?

Which has higher valuation and earnings, RFL or TXMD?

Is RFL or TXMD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools